The global dual specificity tyrosine phosphorylation regulated kinase 1A market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Dual-specificity tyrosine phosphorylation-regulated kinase 1A or DYRK1A is a eukaryotic serine-threonine protein kinase that belongs to the CMGC group and contributes to the development of several human malignancies and cognitive deficits that are observed in down syndrome and Alzheimer's disease. The major factor accelerating the growth of the market is the increasing prevalence of Alzheimer’s disease across the globe.

According to the Alzheimer's Association, more than 6 million Americans of all ages have Alzheimer's. Additionally, in 2021, an estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia out of which 72% are aged 75 or older. Furthermore, as per the same source, one in nine people age 65 and older or 11.3% has Alzheimer's dementia. Moreover, almost two-thirds of Americans with Alzheimer's are women. Apart from this, the number of people aged 65 and older with Alzheimer’s dementia is estimated to grow to 12.7 million by 2050. Hence, the increasing Alzheimer's disease is resulting increased prevalence of cognitive deficits and human malignancies which in turn is driving the growth of the market.

Some major players operating in the market include Pharmasum Therapeutics AS, Carna Biosciences Inc., and NeuroNascent Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Brickell Biotech, Inc. announced that it has entered into a definitive agreement with Voronoi Inc. The agreement was aimed to grant Brickell exclusive, global rights to research, develop and commercialize novel therapeutics generated from a proprietary DYRK1A inhibitor platform.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Pharmasum Therapeutics AS, Carna Biosciences Inc., and NeuroNascent Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Report by Segment

By Type 

    • PST-900

    • NNI-351

    • FX-9847

    • Others

By Application

    • Colon Cancer

    • Down Syndrome

    • Lung Cancer

    • Pancreatic Cancer

    • Others

Global Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa